Targeted Therapies in Myeloproliferative Neoplasms

Myeloproliferative neoplasms comprise a group of chronic clonal stem-cell disorders, which include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Specifically, gain-of-function driver mutations in JAK2, CALR, or MPL stimulate downstream cytokine pathways. Consequently, these genetic alterations grant a distinct survival advantage to aberrant stem cell clones. Understanding these pathways provides critical insights into clinical progression and disease management.

Pathophysiology of Myeloproliferative Neoplasms

Driver mutations typically arise decades before overt clinical manifestations emerge. Moreover, secondary comutations in epigenetic regulators and splicing machinery further accelerate clonal expansion. Chronic systemic inflammation also fosters clonal dominance within the bone marrow niche. As a result, patients experience progressive marrow fibrosis and a marked risk of life-threatening thrombosis. Furthermore, some individuals face leukemic transformation into secondary acute myeloid leukemia, which carries a dismal prognosis.

Limitations of Conventional Therapies

Traditional treatment strategies primarily focus on mitigating thrombosis, alleviating systemic symptoms, and reducing splenomegaly. For instance, clinicians routinely employ cytoreductive agents and phlebotomy to lower hematocrit and platelet counts. In addition, JAK inhibitors provide substantial symptom relief and reduce spleen size in myelofibrosis. However, standard regimens rarely eradicate the malignant clone or permanently alter disease trajectory, with notable exceptions such as pegylated interferon alfa in select cohorts.

Emerging Precision Therapies

Novel therapeutic approaches aim to target disease pathogenesis directly. Specifically, researchers are developing mutant CALR immunotherapies and selective JAK2 V617F inhibitors. Therefore, these targeted modalities offer strong potential to achieve genuine disease modification. In fact, future regimens might accomplish complete clonal eradication and prevent transformation into secondary acute myeloid leukemia through advanced blood disorder management.

Frequently Asked Questions

Q1: What are the primary driver mutations in myeloproliferative neoplasms?

Gain-of-function mutations in JAK2, CALR, and MPL drive cytokine signaling and clonal proliferation in these disorders.

Q2: How do emerging therapies differ from conventional treatments?

Emerging therapies selectively target mutant CALR and JAK2 V617F to achieve disease modification, rather than merely managing symptoms and thrombosis.

References

1. Plo I et al. Myeloproliferative Neoplasms. N Engl J Med. 2026 Aug 20. doi: 10.1056/NEJMra2507867. PMID: 42617115.
2. Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909-1921.
3. Marchetti M et al. ESMO Clinical Practice Guideline: Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms. Ann Oncol. 2024.